



MEDTECS INTERNATIONAL CORPORATION LIMITED
(Incorporated in Bermuda)

MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

1. INTRODUCTION

The Board of Directors (the "**Board**") of Medtecs International Corporation Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 3 December 2024, 27 December 2024, 17 January 2025, 24 January 2025, 27 February 2025, and 27 March 2025 (the "**Announcements**") in relation to, among others, the Winding Up Application and the Court Order in respect of Resilient Medical.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the meanings ascribed to them in the Announcements.

2. MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

Pursuant to Rule 704(22) of the Catalist Rules, the Board wishes to update shareholders that:

- (a) Following the submission by the Company on 21 March 2025 of a proof of debt ("**POD**") to the Liquidator in respect of its claim against RMPL and a reconciliation process, the Liquidator has confirmed acceptance of the POD amounting to approximately USD 29.95 million. The Company has accepted the Liquidator's adjudicated amount in full;
- (b) As of the date of this announcement, the valuation exercise announced previously on 27 March 2025 is still ongoing and the final report has not been issued. There have been no further material developments in the Company's discussions with its principal bankers or trustee since the last update provided on 27 March 2025; and
- (c) The Liquidator had on 28 March 2025 advertised the sale of the nitrile glove factory constructed on the MSEZ Land in two local Cambodian newspapers as part of the liquidation process. The advertisement ran from 28 March 2025 to 18 April 2025. As at the close of the submission period, no offers had been received.

3. FINANCIAL IMPACT

As at the date of this announcement, the Company is still assessing the impact of the Court Order on the net tangible assets per share of the Company and the earnings per share of the Company for the current financial year ending 31 December 2025 as such impact would be affected by the valuation and methodology of the distribution of assets to be determined by the Liquidator. In the event that there is a material impact on the Group's financials or any further material development on this matter, the Company will make a separate announcement in due course.

The Company will also release further announcements to update its shareholders as and when there are material developments in relation to the winding up of Resilient Medical in between the monthly updates.

4. CAUTION IN TRADING

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully. Shareholders and potential investors of the Company are advised to refrain from taking any action with respect to their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

Submitted by Mr Clement Yang, Executive Chairman, on 25 April 2025 to the SGX-ST.

*This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**").*

This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.

The contact persons for the Sponsor are Ms Evelyn Wee (Telephone Number: +65 6232 0724) and Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.